



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyyssw@sina.com

产品名称: **RP-5063**
CAS 号: **1239729-06-6**
产品货号: **S89804**

生物活性:

Description	Brilaroxazine (RP5603) is a potent and orally active multimodal dopamine (DA)/serotonin (5-HT) modulator. Brilaroxazine is a partial agonist of dopamine (DA) D2, D3, and D4 receptors, 5-HT1A (Ki=1.5 nM) and 5-HT2A (Ki=2.5 nM), and has antagonist activity at 5-HT2B (Ki=0.19 nM), and 5-HT7 (Ki=2.7 nM) receptors[1]. Brilaroxazine is an atypical antipsychotic agent, and has the potential to improve cognitive impairments in neuropsychiatric and neurological diseases in vivo[2].																					
IC50 & Target	5-HT1A Receptor 1.5 nM (Ki) 5-HT2A Receptor 2.5 nM (Ki)	5-HT1A Receptor 5-HT2B Receptor 0.19 nM (Ki)	5-HT2A Receptor 5-HT7 Receptor 2.7 nM (Ki)	5-HT2B Receptor D2 Receptor	5-HT7 Receptor D3 Receptor																	
In Vivo	Brilaroxazine (oral gavage; 10 mg/kg; twice daily; 28 days) limits the functional and structural effects of pulmonary arterial hypertension (PAH), with significant improvements in pulmonary hemodynamics, right ventricular (RV) hypertrophy, SO2, and pulmonary blood vessel structural changes[1]. <table><tr><td>Animal Model:</td><td>SD-rats[2]</td></tr><tr><td>Dosage:</td><td>10 mg/kg</td></tr><tr><td>Administration:</td><td>Oral gavage; twice daily; 28 days</td></tr><tr><td>Result:</td><td>Had the efficacy in PAH, and mitigated the functional and structural effects of MCT-induced PAH.</td></tr></table>					Animal Model:	SD-rats[2]	Dosage:	10 mg/kg	Administration:	Oral gavage; twice daily; 28 days	Result:	Had the efficacy in PAH, and mitigated the functional and structural effects of MCT-induced PAH.									
Animal Model:	SD-rats[2]																					
Dosage:	10 mg/kg																					
Administration:	Oral gavage; twice daily; 28 days																					
Result:	Had the efficacy in PAH, and mitigated the functional and structural effects of MCT-induced PAH.																					
Solvent&Solubility	细胞实验: DMSO 中的溶解度 : 100 mg/mL (222.04 mM); 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响, 请使用新开封的 DMSO) <table><tr><td rowspan="4">Preparing Stock Solutions</td><td> Solvent / Mass Concentration </td><td>1 mg</td><td>5 mg</td><td>10 mg</td></tr><tr><td>1 mM</td><td>2.2204 mL</td><td>11.1022 mL</td><td>22.2045 mL</td></tr><tr><td>5 mM</td><td>0.4441 mL</td><td>2.2204 mL</td><td>4.4409 mL</td></tr><tr><td>10 mM</td><td>0.2220 mL</td><td>1.1102 mL</td><td>2.2204 mL</td></tr></table> * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液; 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。 储备液的保存方式和期限: -80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。 动物实验: 请根据您的 实验动物和给药方式 选择适当的溶解方案。 以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液, 再依次添加助溶剂: ——为保证实验结果的可靠性, 澄清的储备液可以根据储存条件, 适当保存; 体内实验的工作液, 建议您现用现配, 当天使用; 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象, 可以通过加热和/或超声的方式助溶 方案 一					Preparing Stock Solutions	Solvent / Mass Concentration	1 mg	5 mg	10 mg	1 mM	2.2204 mL	11.1022 mL	22.2045 mL	5 mM	0.4441 mL	2.2204 mL	4.4409 mL	10 mM	0.2220 mL	1.1102 mL	2.2204 mL
Preparing Stock Solutions	Solvent / Mass Concentration	1 mg	5 mg	10 mg																		
	1 mM	2.2204 mL	11.1022 mL	22.2045 mL																		
	5 mM	0.4441 mL	2.2204 mL	4.4409 mL																		
	10 mM	0.2220 mL	1.1102 mL	2.2204 mL																		



	请依序添加每种溶剂: 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% Saline Solubility: ≥ 2.5 mg/mL (5.55 mM); 澄清溶液 此方案可获得 ≥ 2.5 mg/mL (饱和度未知) 的澄清溶液。 以 1 mL 工作液为例, 取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中, 混合均匀; 再向上述体系中加入 50 μL Tween-80, 混合均匀; 然后再继续加入 450 μL 生理盐水 定容至 1 mL。 生理盐水的配制: 将 0.9 g 氯化钠, 溶解于 ddH₂O 并定容至 100 mL, 可以得到澄清透明的生理盐水溶液。 方案 二 请依序添加每种溶剂: 10% DMSO → 90% Corn Oil Solubility: ≥ 2.5 mg/mL (5.55 mM); 澄清溶液 此方案可获得 ≥ 2.5 mg/mL (饱和度未知) 的澄清溶液, 此方案实验周期在半个月以上的动物实验酌情使用。 以 1 mL 工作液为例, 取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中, 混合均匀。
参考文献	[1]. Reviva Pharmaceuticals Reports RP5063 Positive Efficacy Results for Memory Deficits [2]. Bhat L, et al. Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hypertension rat model. Eur J Pharmacol. 2018 May 15;827:159-166. [3]. L. Bhat, et al. Rp5063 Prevents Monocrotaline Induced Pulmonary Arterial Hypertension In Rats.

完整储备液配制表:

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液; 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。储备液的保存方式和期限: -80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。

可选溶剂	质量 溶剂体积 浓度	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2204 mL	11.1022 mL	22.2045 mL	55.5111 mL
	5 mM	0.4441 mL	2.2204 mL	4.4409 mL	11.1022 mL
	10 mM	0.2220 mL	1.1102 mL	2.2204 mL	5.5511 mL
	15 mM	0.1480 mL	0.7401 mL	1.4803 mL	3.7007 mL
	20 mM	0.1110 mL	0.5551 mL	1.1102 mL	2.7756 mL
	25 mM	0.0888 mL	0.4441 mL	0.8882 mL	2.2204 mL
	30 mM	0.0740 mL	0.3701 mL	0.7401 mL	1.8504 mL
	40 mM	0.0555 mL	0.2776 mL	0.5551 mL	1.3878 mL
	50 mM	0.0444 mL	0.2220 mL	0.4441 mL	1.1102 mL



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyyssw@sina.com

	60 mM	0.0370 mL	0.1850 mL	0.3701 mL	0.9252 mL
	80 mM	0.0278 mL	0.1388 mL	0.2776 mL	0.6939 mL
	100 mM	0.0222 mL	0.1110 mL	0.2220 mL	0.5551 mL



源叶